What’s Ahead for RXi Pharmaceuticals Corporation (RXII) After Today’s Big Increase?

March 14, 2018 - By Richard Conner

The stock of RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a huge mover today! The stock increased 28.12% or $0.9 during the last trading session, reaching $4.1. About 682,695 shares traded or 176.56% up from the average. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 14, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.
The move comes after 6 months positive chart setup for the $9.72M company. It was reported on Mar, 14 by Barchart.com. We have $4.43 PT which if reached, will make NASDAQ:RXII worth $777,280 more.

Analysts await RXi Pharmaceuticals Corporation (NASDAQ:RXII) to report earnings on March, 29. They expect $-0.96 EPS, up 84.00 % or $5.04 from last year’s $-6 per share. After $-1.10 actual EPS reported by RXi Pharmaceuticals Corporation for the previous quarter, Wall Street now forecasts -12.73 % EPS growth.

More notable recent RXi Pharmaceuticals Corporation (NASDAQ:RXII) news were published by: Smallcapnetwork.com which released: “RXi Pharmaceuticals Corp: Building a Foundation for a Breakout” on November 18, 2016, also Quotes.Wsj.com with their article: “RXi Pharmaceuticals Corp. RXII (US: Nasdaq)” published on February 11, 2011, Prnewswire.com published: “RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15 …” on August 09, 2017. More interesting news about RXi Pharmaceuticals Corporation (NASDAQ:RXII) were released by: Prnewswire.com and their article: “RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire …” published on October 12, 2016 as well as Prnewswire.com‘s news article titled: “RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New …” with publication date: January 09, 2017.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $9.72 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: